Skip to main content
OpenTrials

Clinical trial condition

Recurrent Adult Brain Neoplasm

Explore clinical trials studying Recurrent Adult Brain Neoplasm. Study availability and eligibility vary by location and protocol.

14 public trials 0 recruiting studies
Refine in advanced search Browse all conditions

Recurrent Adult Brain Neoplasm trial results

Completed

Lapatinib Ditosylate Before Surgery in Treating Patients With Recurrent High-Grade Glioma

NCT02101905

Conditions
Anaplastic Astrocytoma, Anaplastic Ependymoma, Anaplastic Oligodendroglioma, +23 more
Locations
  • UCLA / Jonsson Comprehensive Cancer Center Los Angeles, California, United States
  • Johns Hopkins University/Sidney Kimmel Cancer Center Baltimore, Maryland, United States
  • Dana-Farber Cancer Institute Boston, Massachusetts, United States
  • Henry Ford Hospital Detroit, Michigan, United States
View Trial Details
Completed

Imatinib Mesylate in Treating Patients With Recurrent Brain Tumor

NCT00049127

Conditions
Adult Anaplastic Oligodendroglioma, Adult Mixed Glioma, Adult Oligodendroglioma, +17 more
Locations
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Saint Francis Hospital and Medical Center Hartford, Connecticut, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
  • Rush - Copley Medical Center Aurora, Illinois, United States
View all 229 locations
View Trial Details
Completed

Dasatinib in Treating Patients With Recurrent Glioblastoma Multiforme or Gliosarcoma

NCT00423735

Conditions
Adult Giant Cell Glioblastoma, Adult Glioblastoma, Adult Gliosarcoma, +19 more
Locations
  • Mobile Infirmary Medical Center Mobile, Alabama, United States
  • Arizona Oncology Services Foundation Scottsdale, Arizona, United States
  • The University of Arizona Medical Center-University Campus Tucson, Arizona, United States
  • Sutter Cancer Centers Radiation Oncology Services-Auburn Auburn, California, United States
View all 188 locations
View Trial Details
Completed

Sorafenib Tosylate and Temsirolimus in Treating Patients With Recurrent Glioblastoma

NCT00329719

Conditions
Adult Glioblastoma, Adult Gliosarcoma, Astrocytoma, +18 more
Locations
  • Providence Alaska Medical Center Anchorage, Alaska, United States
  • Mayo Clinic in Arizona Scottsdale, Arizona, United States
  • Smilow Cancer Hospital Care Center at Saint Francis Hartford, Connecticut, United States
  • Mayo Clinic in Florida Jacksonville, Florida, United States
View all 190 locations
View Trial Details
Completed

Bevacizumab and Irinotecan or Temozolomide in Treating Patients With Recurrent or Refractory Glioblastoma Multiforme or Gliosarcoma

NCT00433381

Conditions
Adult Glioblastoma, Adult Gliosarcoma, Astrocytoma, +18 more
Locations
  • Mobile Infirmary Medical Center Mobile, Alabama, United States
  • Fairbanks Memorial Hospital Fairbanks, Alaska, United States
  • Arizona Oncology Services Foundation Scottsdale, Arizona, United States
  • Alta Bates Summit Medical Center-Herrick Campus Berkeley, California, United States
View all 93 locations
View Trial Details
Completed

Bevacizumab With or Without Anti-Endoglin Monoclonal Antibody TRC105 in Treating Patients With Recurrent Glioblastoma Multiforme

NCT01648348

Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, +23 more
Locations
  • University of Arkansas for Medical Sciences Little Rock, Arkansas, United States
  • Saint Jude Medical Center Fullerton, California, United States
  • Saint Joseph Hospital - Orange Orange, California, United States
  • Sharp Memorial Hospital San Diego, California, United States
View all 308 locations
View Trial Details
Completed

Bendamustine Hydrochloride in Treating Patients With Recurrent or Progressive Anaplastic Glioma

NCT00823797

Conditions
Adult Anaplastic Astrocytoma, Adult Anaplastic Oligodendroglioma, Adult Giant Cell Glioblastoma, +22 more
Locations
  • Northwestern University Chicago, Illinois, United States
  • Huntsman Cancer Institute/University of Utah Salt Lake City, Utah, United States
  • Fred Hutch/University of Washington Cancer Consortium Seattle, Washington, United States
View Trial Details

Related conditions